Right now, the HALT Study is underway to provide the substantial evidence of effectiveness necessary for the full FDA approval of Felycin-CA1 (referred to as TRIV202 in HALT) for the management of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback